Votrient Maintenance Therapy Fails to Improve Survival in Advanced Ovarian Cancer Patients, Trial Results Show

Votrient Maintenance Therapy Fails to Improve Survival in Advanced Ovarian Cancer Patients, Trial Results Show
Maintenance treatment with Votrient (pazopanib) does not extend the survival of newly diagnosed advanced ovarian cancer patients whose disease did not worsen after surgery and first-line chemotherapy, according to Phase 3 trial data. However, the approach extended the time until disease worsening or death — as shown in a prior analysis — which delayed the need

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *